Trial Outcomes & Findings for Clinical Trial of Estrogen for Postpartum Depression (NCT NCT00059228)

NCT ID: NCT00059228

Last Updated: 2018-06-13

Results Overview

The Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory for measuring the severity of depression. Higher total scores indicate more severe depressive symptoms. The range of scores vary from 0 to 63 (highest possible total) for the whole test. A score of 0 - 10 indicates minimal depression, while a score of over 40 indicates extreme depression. No subscales were used for this outcome.

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

12 participants

Primary outcome timeframe

6 weeks

Results posted on

2018-06-13

Participant Flow

Participant milestones

Participant milestones
Measure
Estradiol
Estradiol transdermal patch 100mcg
Placebo
Placebo transdermal patch
Overall Study
STARTED
6
6
Overall Study
COMPLETED
6
5
Overall Study
NOT COMPLETED
0
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Clinical Trial of Estrogen for Postpartum Depression

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Estradiol
n=6 Participants
Estradiol transdermal patch 100mcg
Placebo
n=6 Participants
Placebo transdermal patch
Total
n=12 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
6 Participants
n=99 Participants
6 Participants
n=107 Participants
12 Participants
n=206 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Sex: Female, Male
Female
6 Participants
n=99 Participants
6 Participants
n=107 Participants
12 Participants
n=206 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
5 Participants
n=99 Participants
5 Participants
n=107 Participants
10 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
2 Participants
n=99 Participants
2 Participants
n=107 Participants
4 Participants
n=206 Participants
Race (NIH/OMB)
White
2 Participants
n=99 Participants
3 Participants
n=107 Participants
5 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants

PRIMARY outcome

Timeframe: 6 weeks

Population: The analysis included only those subjects who had taken Estradiol and Placebo

The Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory for measuring the severity of depression. Higher total scores indicate more severe depressive symptoms. The range of scores vary from 0 to 63 (highest possible total) for the whole test. A score of 0 - 10 indicates minimal depression, while a score of over 40 indicates extreme depression. No subscales were used for this outcome.

Outcome measures

Outcome measures
Measure
Estradiol
n=6 Participants
Estradiol transdermal patch 100mcg
Placebo
n=6 Participants
Placebo transdermal patch
Beck Depression Inventory
15.84 Units on a scale
Standard Error 3.91
5.3 Units on a scale
Standard Error 3.19

PRIMARY outcome

Timeframe: Baseline

Population: The analysis included only those subjects who had taken Estradiol and Placebo

The Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory for measuring the severity of depression. Higher total scores indicate more severe depressive symptoms. The range of scores vary from 0 to 63 (highest possible total) for the whole test. A score of 0 - 10 indicates minimal depression, while a score of over 40 indicates extreme depression. No subscales were used for this outcome.

Outcome measures

Outcome measures
Measure
Estradiol
n=6 Participants
Estradiol transdermal patch 100mcg
Placebo
n=6 Participants
Placebo transdermal patch
Beck Depression Inventory
26 units on a scale
Standard Error 2.62
27.67 units on a scale
Standard Error 3.72

Adverse Events

Estradiol

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Estradiol
n=6 participants at risk
Estradiol transdermal patch 100mcg
Placebo
n=6 participants at risk
Placebo transdermal patch
Gastrointestinal disorders
Nausea
0.00%
0/6
16.7%
1/6

Additional Information

Schmidt, Peter

National Institute of Mental Health

Phone: +1 301 496 6120

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place